journal article·2009-10Open access

Poly(ω-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery

Jie Liu, Zhaozhong Jiang, Shengmin Zhang, W. Mark Saltzman

Biomaterials· Volume 30· Issue 29

Abstract

In this study, we show that degradable particles of a hydrophobic polymer can effectively deliver drugs to tumors after i.v. administration. Free-standing nanoparticles with diameters of 100-300 nm were successfully fabricated from highly hydrophobic, biodegradable poly(omega-pentadecalactone-co-butylene-co-succinate) (PPBS) copolyesters. PPBS copolymers with various compositions (20-80 mol% PDL unit contents) were synthesized via copolymerization of omega-pentadecalactone (PDL), diethyl succinate (DES), and 1,4-butanediol (BD) using Candida antarctica lipase B (CALB) as the catalyst. Camptothecin (CPT, 12-22%) was loaded into PPBS nanoparticles with high encapsulation efficiency (up to 96%) using a modified oil-in-water single emulsion technique. The CPT-loaded nanoparticles had a zeta potential of about -10 mV. PPBS particles were non-toxic in cell culture. Upon encapsulation, the active lactone form of CPT was remarkably stabilized and no lactone-to-carboxylate structural conversion was observed for CPT-loaded PPBS nanoparticles incubated in both phosphate-buffered saline (PBS, pH=7.4) and DMEM medium for at least 24 h. In PBS at 37 degrees C, CPT-loaded PPBS nanoparticles showed a low burst CPT release (20-30%) within the first 24 h followed by a sustained, essentially complete, release of the remaining drug over the subsequent 40 days. Compared to free CPT, CPT-loaded PPBS nanoparticles showed a significant enhancement of cellular uptake, higher cytotoxicity against Lewis lung carcinoma and 9L cell lines in vitro, a longer circulation time, and substantially better antitumor efficacy in vivo. These results demonstrate the potential of PPBS nanoparticles as long-term stable and effective drug delivery systems in cancer therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Pneumocystis jirovecii pneumonia detection and treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (47)

Show source-provided references
1. Nanoparticles of biodegradable polymers for new-concept chemotherapy10.1586/17434440.1.1.115 ↗
2. Nanocarriers as an emerging platform for cancer therapy10.1038/nnano.2007.387 ↗
3. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy10.1016/j.jconrel.2008.01.013 ↗
4. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting10.1016/S0065-2571(00)00013-3 ↗
5. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect10.1016/j.ejpb.2008.11.010 ↗
6. Plant antitumor agents. I. Isolation and structure of camptothecin a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata10.1021/ja00968a057 ↗
7. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogs10.1002/jps.2600810718 ↗
8. Differential interactions of camptothecin lactone and carboxylate forms with human blood components10.1021/bi00200a013 ↗
9. Camptothecin delivery methods10.1023/A:1020427227285 ↗
10. Topoisomerase-I inhibitors – topotecan and irenotecan10.1016/0305-7372(94)90011-6 ↗
12. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin10.1016/j.jconrel.2008.02.005 ↗
13. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions
14. Cationic lipid complexed camptothecin (EndoTAG((R))-2) improves antitumoral efficacy by tumor vascular targeting10.4161/cbt.6.6.4207 ↗
15. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles10.1016/j.jconrel.2006.03.012 ↗
16. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability10.1016/j.ijpharm.2005.10.030 ↗
17. Efficacy of camptothecin and polymer-conjugated camptothecin in tumor spheroids and solid tumors10.1163/156856207782177918 ↗
18. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker10.1007/s002800050837 ↗
19. In vitro cytotoxicity and in vivo distribution after direct delivery of PEG–camptothecin conjugates to the rat brain10.1021/bc034180o ↗
20. Poly(d,l-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin10.1016/S0168-3659(99)00122-4 ↗
21. Evaluation of antimetastatic activity and systemic toxicity of camptothecin-loaded microspheres in mice injected with B16-F10 melanoma cells
22. Biodegradable nanoparticles for cytosolic delivery of therapeutics10.1016/j.addr.2007.06.003 ↗
23. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles10.1021/mp034002c ↗
24. Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors10.1023/A:1007591721877 ↗
25. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain10.1016/S0168-3659(99)00007-3 ↗
26. Improved dissolution and cytotoxicity of camptothecin incorporated into oxidized-cellulose microspheres prepared by spray drying10.1081/PDT-100002254 ↗
27. Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells10.1021/bc800057g ↗
28. Particle characteristics and biodistribution of camptothecin-loaded PLA/(PEG–PPG–PEG) nanoparticles10.1080/10717540701827154 ↗
29. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin10.1016/j.nano.2009.02.002 ↗
30. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent10.1023/A:1012126301290 ↗
31. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells10.1016/j.biomaterials.2009.01.057 ↗
32. Lipase-catalyzed synthesis of aliphatic polyesters via copolymerization of lactone, dialkyl diester, and diol10.1021/bm800814m ↗
33. Simple non-ion-paired high-performance liquid chromatographic method for simultaneous quantitation of carboxylate and lactone forms of 14 new camptothecin derivatives10.1016/S1570-0232(03)00485-9 ↗
34. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating10.1016/S0378-5173(02)00129-1 ↗
35. Pharmacokinetics and biodistribution of nanoparticles10.1021/mp800049w ↗
36. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus10.1021/mp8001254 ↗
37. Freeze-drying of nanoparticles: formulation, process and storage considerations10.1016/j.addr.2006.09.017 ↗
38. Stability and freeze-drying of cyclosporine loaded poly(d,l lactide-glycolide) carriers10.1016/S0928-0987(98)00066-9 ↗
39. Influence of the stabilizer coating layer on the purification and freeze-drying of poly(d,l-lactic acid) nanoparticles prepared by an emulsion–diffusion technique10.3109/02652049809006840 ↗
40. Dynamics of endocytosis and exocytosis of poly(d,l-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells10.1023/A:1022219003551 ↗
41. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers10.1023/B:PHAM.0000022411.47059.76 ↗
42. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression10.1023/B:PHAM.0000016250.56402.99 ↗
43. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells10.1002/(SICI)1097-0215(19991112)83:4<491::AID-IJC10>3.0.CO;2-M ↗
44. In vivo cancer targeting and imaging with semiconductor quantum dots10.1038/nbt994 ↗
45. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer–lipid hybrid nanoparticle system10.1124/jpet.106.101154 ↗
46. Determination of camptothecin in biological-fluids using reversed-phase high-performance liquid-chromatography with fluorescence detection10.1016/S0378-4347(00)82339-7 ↗
47. Preparation and antitumor characteristics of PLA/(PEG–PPG–PEG) nanoparticles loaded with camptothecin10.1016/j.ejpb.2007.01.012 ↗